AUTOLOGOUS T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED TO B-CELL MATURATION ANTIGEN (BCMA) IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (GMG).
- Registry ID
- MG-001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- CARTESIAN THERAPEUTICS, INC.
- Start date
- 2023-03-31
- Last update
- 2021-07-21
Conditions
- GENERALIZED MYASTHENIA GRAVIS (MG)."
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DESCARTES-08 IN PATIENTS WITH ACETYLCHOLINE RECEPTOR ANTIBODY-POSITIVE GENERALIZED MYASTHENIA GRAVIS
- AN OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND ACTIVITY OF EFGARTIGIMOD PH20 SC IN PARTICIPANTS FROM 2 TO LESS THAN 18 YEARS OF AGE WITH GENERALIZED MYASTHENIA GRAVIS
- A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 3, PARALLEL-GROUP
DESIGN STUDY EVALUATING THE EFFICACY AND SAFETY OF EFGARTIGIMOD IV IN ADULT
PARTICIPANTS WITH ACETYLCHOLINE RECEPTOR BINDING ANTIBODY SERONEGATIVE
GENERALIZED MYASTHENIA GRAVIS
- A LONG-TERM, SINGLE-ARM, OPEN-LABEL, MULTICENTER, FOLLOW-ON TRIAL OF ARGX- 113-2006 TO EVALUATE SAFETY OF EFGARTIGIMOD ADMINISTERED INTRAVENOUSLY IN CHILDREN WITH GENERALIZED MYASTHENIA GRAVIS
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ALXN1720 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
- A PHASE 3, MULTI-CENTER, RANDOMIZED, QUADRUPLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BATOCLIMAB AS INDUCTION AND MAINTENANCE THERAPY IN ADULT PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS (GMG)
View on source registry